Skip to main content
PrintBio is a privately held, clinical- and commercial-stage biotechnology company and leader in regenerative medicine using novel 3D-bioprinting and material science technologies to deliver safe, functional and personalized products and living tissues and organs, engineered and produced on-demand for patients.  The Company was founded and is led by an experienced team of biotechnology founders and executives.

 

For questions regarding investment opportunities, email: investors@printbio.com

Learn More

Pulmatrix and Eos merge to advance gerotherapeutics

| News | No Comments
Pulmatrix and Eos merge to advance gerotherapeutics

Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan

| News, Press Releases | No Comments
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan • Combined company to operate as Eos SENOLYTIX, a first-in-class anti-aging biotechnology company • $19…

PrintBio Contributes 3D Bioprinting Expertise to ARPA-H PRINT Program for Kidney Bioprinting

| Press Releases | No Comments
PrintBio, a regenerative medicine and bioprinting company, today announced its participation in a major ARPA-H PRINT Program initiative aimed at addressing the nation’s growing organ shortage through the development of…